erlotinib has been researched along with vincristine in 7 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (vincristine) | Trials (vincristine) | Recent Studies (post-2010) (vincristine) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 246 | 0 | 117 |
| Protein | Taxonomy | erlotinib (IC50) | vincristine (IC50) |
|---|---|---|---|
| Tubulin beta-4A chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 0.5 | |
| Beta-tubulin | Leishmania donovani | 1 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 1.8 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 0.5 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1.8 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1.8 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdelazeem, AH; Amjad, MW; Bukhari, SNA; Qin, HL; Raja, MAG; Youssif, BGM; Zha, GF | 1 |
| Abdelazeem, AH; Abdelgawad, MA; Abdelrahman, MH; Bukhari, SNA; Ibrahim, HM; Mohamed, MFA; Salem, OIA; Treambleau, L; Youssif, BGM | 1 |
| Abdelatef, SA; Abdelazeem, AH; Abdellatif, KRA; Amin, NH; El-Saadi, MT; Omar, HA | 1 |
1 review(s) available for erlotinib and vincristine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for erlotinib and vincristine
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclohexanones; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Oximes; Pyrazines; Structure-Activity Relationship | 2017 |
Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Indoles; Male; Mice; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Polymerization; Proto-Oncogene Proteins B-raf; Pyrazines; Reactive Oxygen Species; Small Molecule Libraries; Structure-Activity Relationship; Tubulin | 2018 |
Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
Topics: Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Spiro Compounds; Structure-Activity Relationship | 2018 |